ClinicalTrials.gg
CompletedNCT07540624Updated Nov 12, 2026

Efficacy of Chlorhexidine and Morus Nigra Mouthwashes After Periodontal Treatment

An interventional study of 0.12% Chlorhexidine Gluconate Mouthwash and 5% Morus Nigra Mouthwash in Periodontitis and Periodontal Disease, sponsored by Inonu University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Inonu University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Mar 2025, registered Mar 2026).
Updated Nov 12, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Periodontitis by Inonu University — none open to participants now, none under way, none of them phase 3. Periodontitis · Inonu University.

Started
2025
with 2 others
No phase
2 of 11
none open now
Registered
3rd of 11
by date

Among the 11 studies in Periodontitis by Inonu University, this one is one of 3 that started in 2025, is one of 2 with no phase, and was the 3rd registered.

Periodontitis

1,242 studies on the registry are indexed under Periodontitis; 304 are open to participants now.

Browse Periodontitis studies →

Open to participants now

None of the 11 studies in Periodontitis by Inonu University is open now. The open studies under Periodontitis, anywhere →

Where they have run

Who these studies take

Of the 163 Periodontitis studies recruiting now, 80 (49%) set no upper age limit and 62 (38%) stop at 75 or younger; 12 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Periodontitis by Inonu University as a file.
02

Study summary

This study aims to evaluate and compare the clinical, biochemical, and microbiological effects of chlorhexidine and Morus nigra mouthwashes used as an adjunct to non-surgical periodontal treatment (scaling and root planing - SRP) in patients with periodontal diseases. The participants will be divided into three groups: a control group receiving only SRP, a group receiving SRP combined with chlorhexidine mouthwash, and a group receiving SRP combined with Morus nigra mouthwash. Clinical periodontal parameters, gingival crevicular fluid levels of inflammatory markers (including TNF-a, IL-1b, and IL-10), and subgingival plaque microbiological profiles (such as red complex bacteria and Fusobacterium) will be evaluated at baseline, 1 month, and 3 months after the treatment.

03

Conditions studied

  • Periodontitis
  • Periodontal Disease

Keywords

  • Chlorhexidine
  • Morus nigra
  • Mouthwash
  • Scaling and Root Planing
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with periodontitis.
  • Systemically healthy individuals.
  • Patients aged between 18 and 65 years.
  • Presence of at least 20 natural teeth.
  • Volunteering to participate in the study and signing the form.

Exclusion criteria

Exclusion Criteria:

  • Presence of any systemic disease that may affect periodontal health or systemic inflammatory response (e.g., Diabetes Mellitus, immunological disorders).
  • Current smokers or use of any tobacco products.
  • Pregnancy or lactation.
  • Use of systemic antibiotics, anti-inflammatory drugs, or medications within the last 6 months.
  • Having received any non-surgical or surgical periodontal treatment within the last 6 months.
  • Known allergy or sensitivity to chlorhexidine or Morus nigra (blackberry) extracts.
  • Patients using orthodontic appliances.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Active comparator
    Control Group

    Non-surgical periodontal treatment consisting of full-mouth scaling and root planing (SRP) using ultrasonic and hand instruments.

    Procedure: Scaling and Root Planing (SRP)

  • Experimental
    Chlorhexidine Group

    As an adjunct to scaling and root planing, patients will rinse with 15 ml of 0.12% chlorhexidine gluconate mouthwash twice a day (morning and evening) for 1 minute. The duration of the intervention is 14 days.

    Drug: 0.12% Chlorhexidine Gluconate Mouthwash · Procedure: Scaling and Root Planing (SRP)

  • Experimental
    Morus Nigra Group

    As an adjunct to scaling and root planing, patients will rinse with 15 ml of a standardized mouthwash containing 5% Morus nigra extract twice a day (morning and evening) for 1 minute. The duration of the intervention is 14 days.

    Drug: 5% Morus Nigra Mouthwash · Procedure: Scaling and Root Planing (SRP)

Interventions

  • DrugChlorhexidine gluconateStudies of Chlorhexidine gluconateChlorhexidine gluconate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    As an adjunct to SRP, patients were instructed to rinse with 15 ml of 0.12% chlorhexidine gluconate mouthwash twice daily (morning and evening) for 1 minute. The treatment duration was 14 days.

  • Drug5% Morus Nigra Mouthwash

    As an adjunct to SRP, patients were instructed to rinse with 15 ml of a standardized mouthwash containing 5% Morus nigra extract twice daily (morning and evening) for 1 minute. The treatment duration was 14 days.

  • ProcedureScaling and Root Planing (SRP)

    All patients in the study underwent non-surgical periodontal therapy consisting of full-mouth scaling and root planing (SRP) using both ultrasonic devices and hand instruments.

06

What researchers measure

Primary outcomes

  1. Gingival Index (GI)

    Evaluation of gingival inflammation using a scale of 0 to 3.

    Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.

  2. Plaque Index (PI)

    Evaluation of plaque accumulation using a scale of 0 to 3.

    Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.

  3. Probing Depth (PD)

    Measurement of the distance from the gingival margin to the bottom of the periodontal pocket.

    Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.

  4. Clinical Attachment Level (CAL)

    Measurement of the distance from the cementoenamel junction to the bottom of the periodontal pocket.

    Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.

  5. Bleeding on Probing (BOP)

    Evaluation of the presence or absence of bleeding within 30 seconds after probing. The result is recorded as a percentage of sites that bleed.

    Time frame: Baseline (Day 0), 1 month, and 3 months after periodontal treatment.

Secondary outcomes

  1. Change in Gingival Crevicular Fluid (GCF) Inflammatory Markers

    Analysis of TNF-a, IL-1b, and IL-10 levels in the gingival crevicular fluid using ELISA (or specific biochemical assay) to evaluate the local inflammatory response

    Time frame: At baseline, 1 month, and 3 months after treatment

  2. Change in Subgingival Plaque Microbiological Profile

    Evaluation of subgingival plaque samples to determine the levels of red complex bacteria and Fusobacterium nucleatum using PCR (Polymerase Chain Reaction) analysis

    Time frame: At baseline, 1 month, and 3 months after treatment

07

Study locations

1 site
  • Inonu University Faculty of Dentistry
    Battalgazi, Malatya 44300, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data that underlie the results reported in the published article will be shared

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be available beginning 6 months and ending 36 months following article publication.

Access criteria: Data will be shared with researchers who provide a methodologically sound proposal. Requests for data sharing should be directed to the principal investigator via email

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jan 2026, 9 months.

Of 484 non-industry interventional studies with no phase under Periodontitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 9 months is below that.

Counting every sponsor, half of 498 studies reached it within 15 months; a quarter within 8 and three quarters within 31.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: start May 2025 → Mar 2025, primary completion Jun 2026 → Jan 2026 and completion Jul 2026 → Jan 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 20, 2026
StartActual
Mar 8, 2025was May 2025
Primary completionActual
Jan 1, 2026was Jun 2026
CompletionActual
Jan 1, 2026was Jul 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 4, 2026
Start date
May 8, 2025→Mar 8, 2025
Nov 12, 2026
Primary completion
Jun 1, 2026→Jan 1, 2026
Nov 12, 2026
Study completion
Jul 1, 2026→Jan 1, 2026
Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    Start date May 8, 2025→Mar 8, 2025
    Primary completion Jun 1, 2026→Jan 1, 2026
    Study completion Jul 1, 2026→Jan 1, 2026
    + 2 other changes: description and design details
  2. Nov 4, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07540624
Lead sponsor
Inonu University
Responsible party
Burak Koçak (Research Assistant, Inonu University) — Principal investigator
First posted
Apr 20, 2026
Start date
Mar 8, 2025
Primary completion
Jan 1, 2026
Completion
Jan 1, 2026
Last update
Nov 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Chlorhexidine gluconate

Start the discussion